Thursday, July 31, 2008

Amgen Licenses Molecule for the Treatment of Chronic and Neuropathic Pain to Ortho-McNeil-Janssen Pharmaceuticals, Inc.

 THOUSAND OAKS, Calif. – July 31, 2008 – Amgen (NASDAQ: AMGN) today announced that it has licensed a clinical stage molecule for the treatment of chronic and neuropathic pain to Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), a Johnson & Johnson company. The terms of the agreement include a $50 million upfront payment, the potential for $385 million in success-based milestones and additional sales based milestones and royalties on sales.

Read the rest of this entry

Posted in Press Releases

Wednesday, July 30, 2008

Amgen Issues Statement in Response to Revised ESA Labeling Received from the FDA Today

Amgen issued the following statement in response to the receipt today of the complete response on the revised ESA labeling from the FDA.

“This label is consistent with our expectations.  We will soon be communicating the revised product labeling for ESAs to both physicians and patients.”

The potential impact of this revised label was factored into our updated guidance announced July 28, 2008.

Read the rest of this entry

Posted in

Friday, July 25, 2008

Amgen Announces Positive Top-Line Results for Denosumab Pivotal Postmenopausal Osteoporosis Trial

Study Met Primary Endpoint of Reducing New Vertebral Fractures and Secondary Endpoints of Reducing Time to First Non-Vertebral and Hip Fractures; Adverse Events Similar to Placebo

THOUSAND OAKS, Calif. – July 25, 2008 – Amgen (NASDAQ: AMGN) today announced findings from the pivotal fracture trial evaluating its RANK Ligand inhibitor, denosumab, in the treatment of postmenopausal osteoporosis.

Read the rest of this entry

Posted in Press Releases

Wednesday, July 23, 2008

Nplate Update

The FDA notified Amgen that they will not issue a decision on Nplate™ (romiplostim) by the PDUFA deadline of July 23, 2008. Amgen continues to work with the FDA to assist in the completion of the review process. We remain optimistic that a final decision will be made soon, but Amgen cannot speculate on the timing of the FDA’s response.

Read the rest of this entry

Posted in

Monday, July 21, 2008

250 Amgen Scholars from 10 Premier Universities Convene for National Summer Symposium to Explore Drug Discovery & Development

Annual Symposium Offered Opportunity to Meet Peers and Leading Scientists; Discuss Hands-On Summer Research Projects

THOUSAND OAKS, Calif. and CAMBRIDGE, Mass. – July 21, 2008 – From July 19-21, nearly 250 undergraduate students from across the country gathered at the University of California, Los Angeles (UCLA) to share their summer research projects and gain insight into how scientific research can translate into the discovery and development of important drugs for patients.

Read the rest of this entry

Posted in Philanthropy, Press Releases